Voglar-GM 2mg/500mg/0.3mg Tablet SR
Marketer
Metlar Formulations
Salt Composition
Glimepiride (2mg) + Metformin (500mg) + Voglibose (0.3mg)
Overview Voglar-GM 2mg/500mg/0.3mg Tablet SR
Diabex-Trio 2mg/500mg/0.3mg Extended-Release Tablets are classified as antidiabetic medications. This combination therapy is indicated for adult patients with type 2 diabetes mellitus to manage blood glucose concentrations. Administer Diabex-Trio with food, consistently at the same time daily for optimal efficacy. Dosage will be determined by your physician and may be adjusted based on your glycemic response. Continue this medication even if feeling well or achieving blood sugar targets; discontinuation without medical supervision risks hyperglycemia and potential complications such as nephropathy, retinopathy, neuropathy, and limb loss. Remember, this is one component of a comprehensive diabetes management plan encompassing a balanced diet, regular physical activity, and weight management as directed by your doctor. Lifestyle choices significantly impact diabetes control. Hypoglycemia (low blood sugar) is a common adverse effect. Familiarize yourself with hypoglycemic symptoms (e.g., sweating, lightheadedness, headache, tremor) and appropriate countermeasures. Maintain regular meals and carry readily available glucose sources (e.g., sweets, juice). Alcohol consumption elevates hypoglycemia risk and should be avoided. Other potential side effects include altered taste perception, nausea, diarrhea, abdominal discomfort, cephalalgia, edema, visual disturbances, bone fractures, and upper respiratory infections. Weight gain may occur. This medication is contraindicated in type 1 diabetes, diabetic ketoacidosis, and severe hepatic or renal impairment. Disclose any history of cardiovascular disease to your doctor before starting treatment; suitability may be affected. Pregnant or lactating individuals should consult their physician before initiating Diabex-Trio. Regular blood glucose monitoring and periodic blood tests (complete blood count and liver function tests) may be recommended by your doctor.
Primary Ingredients of Voglar-GM 2mg/500mg/0.3mg Tablet SR
No text provided. Please provide the text you wish me to rephrase.
Uses of Voglar-GM 2mg/500mg/0.3mg Tablet SR
Managing type 2 diabetes
Major Benefits of Voglar-GM 2mg/500mg/0.3mg Tablet SR:
Follow your doctor's instructions precisely regarding the dosage and treatment length for this medication. The Voglar-GM 2mg/500mg/0.3mg Tablet SR should be swallowed whole, without chewing, crushing, or breaking. Administer this medication on an empty stomach.
Common Side effects of Voglar-GM 2mg/500mg/0.3mg Tablet SR:
- Nausea
- Diarrhea
- Abdominal pain
- Hypoglycemia (low blood glucose level)
- Loss of appetite
How to use Voglar-GM 2mg/500mg/0.3mg Tablet SR:
Follow your doctor's instructions precisely regarding the dosage and treatment length for this medication. Ingest the Voglar-GM 2mg/500mg/0.3mg Tablet SR whole; do not break, crush, or chew it. Administer on an empty stomach.
How Voglar-GM 2mg/500mg/0.3mg Tablet SR works:
Voglar-GM SR tablets (2mg/500mg/0.3mg) contain a triple-action antidiabetic formulation.
SAFETY ADVICE
AlcoholUNSAFE
Combining Voglar-GM 2mg/500mg/0.3mg SR tablets with alcohol is not recommended due to safety concerns.
PregnancyCONSULT YOUR DOCTOR
The use of Voglar-GM 2mg/500mg/0.3mg Tablet SR during pregnancy may pose risks. While human research is scarce, animal studies indicate potential harm to the fetus. A physician will assess the potential advantages against any possible risks prior to prescribing. Physician consultation is advised.
Breast feedingCONSULT YOUR DOCTOR
Use of Voglar-GM 2mg/500mg/0.3mg SR tablets while breastfeeding is likely unsafe. Available human data indicate potential transfer to breast milk, posing a risk to the infant.
DrivingCAUTION
Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these blood sugar imbalances.
KidneyUNSAFE
The extended-release Voglar-GM 2mg/500mg/0.3mg tablet is likely unsafe for individuals with kidney impairment and its use should be forgone. Medical advice is recommended. Furthermore, Voglar-GM 2mg/500mg/0.3mg Tablet SR is contraindicated in patients exhibiting severe kidney dysfunction.
LiverCAUTION
Patients with liver impairment should use Voglar-GM 2mg/500mg/0.3mg SR tablets cautiously, potentially requiring dosage modification. Consultation with a physician is advised. For those with mild to moderate hepatic dysfunction, initiation at a reduced dose is typical; however, the medication is unsuitable for individuals with severe liver disease.
What if you forget to take Voglar-GM 2mg/500mg/0.3mg Tablet SR :
Should you forget a Voglar-GM 2mg/500mg/0.3mg SR Tablet dose, administer it immediately. However, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Voglar-GM 2mg/500mg/0.3mg Tablet SR
| Label | Value |
|---|---|
| Developing Habits | No. |
| Treatment Category | Diabetes Management |
3,018 People bought this recently